187
Views
4
CrossRef citations to date
0
Altmetric
Review

Emerging drugs for the acute treatment of relapses in adult neuromyelitis optica spectrum disorder patients

ORCID Icon, &
Pages 91-98 | Received 17 Dec 2021, Accepted 25 Mar 2022, Published online: 30 Mar 2022

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Hai-yun Li, Cai-san Cui, Hui-min Yang, Wen-jing Jiang & Xiang-dong Yang. (2023) Factors associated with disease relapse rate in the Neuromyelitis optica spectrum disorder. International Journal of Neuroscience 0:0, pages 1-6.
Read now
Woojun Kim & Ho Jin Kim. (2023) An update on biologic treatments for neuromyelitis optica spectrum disorder. Expert Review of Clinical Immunology 19:1, pages 111-121.
Read now

Articles from other publishers (2)

Verónica Tkachuk, María Eugenia Balbuena Aguirre, Ricardo Alonso, Andrés Barboza, Susana del Valle Liwacki, Carolina Mainella, Juan I. Rojas, Berenice Anabel Silva, Darío Tavolini, Gisela Zanga, Pablo López, Guillermo Delgado Garcia & Edgar Carnero Contentti. (2023) Barriers to access and unmet needs to neuromyelitis optica spectrum disorders care in an Argentinean cohort. Multiple Sclerosis and Related Disorders 70, pages 104485.
Crossref
Itay Lotan & Michael Levy. (2022) New Treatment Perspectives for Acute Relapses in Neuromyelitis Optica Spectrum Disorder. Transfusion Medicine Reviews 36:4, pages 230-232.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.